Janux Therapeutics (JANX) Return on Equity (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Return on Equity for 5 consecutive years, with 0.12% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 4.0% to 0.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.12% through Dec 2025, down 4.0% year-over-year, with the annual reading at 0.11% for FY2025, 1.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.12% at Janux Therapeutics, down from 0.1% in the prior quarter.
  • The five-year high for Return on Equity was 0.41% in Q1 2021, with the low at 0.22% in Q2 2023.
  • Average Return on Equity over 5 years is 0.1%, with a median of 0.11% recorded in 2025.
  • The sharpest move saw Return on Equity plummeted -53bps in 2022, then grew 15bps in 2024.
  • Over 5 years, Return on Equity stood at 0.09% in 2021, then plummeted by -120bps to 0.19% in 2022, then grew by 13bps to 0.17% in 2023, then surged by 51bps to 0.08% in 2024, then crashed by -43bps to 0.12% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.12%, 0.1%, and 0.11% for Q4 2025, Q3 2025, and Q2 2025 respectively.